SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NVestor who wrote (96)3/4/1997 9:25:00 PM
From: Dauntless   of 834
 
You're certainly on the right track - the test to investigate for coagulation is the ACT (activated clotting time) - very common but I don't know the cost.

The TOTAL cost of heparin is a very subtle question - there are IV supplies, monitoring, fluid etc. &.... do you want to add in the cost of the complications for those patients that develop HIT??. This is a difficult question to answer & sometimes not perceived as worth the effort because the departmental/political situation with the pharmacy in the hospital does not apply resultant saving to the proper cost center. For example - to use TXB's drug in place of heparin would add significantly to the pharmacy's costs - but any resultant savings would be realized by & credited to the ICU.

This is not an insurmountable problem but will require huge educational effort by the company. Fortunately, it is already underway with seminars & future papers. Hang in there - I believe TXB is still a huge bargain - I bought at $3, $4 & $6.

GO TXB!!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News